Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the LawAbortion Drugs

21 states back Louisiana’s lawsuit against FDA abortion pill rules

Twenty-one states have joined Louisiana’s lawsuit against the federal government challenging the U.S. Food and Drug Administration’s (FDA’s) relaxation of abortion pill rules, in defiance of the Trump administration’s call for the matter to be indefinitely postponed.

Continue Reading at LifeSiteNews >>

Latest Posts

November 9, 2026 Minimalist illustration of a small, flat-roofed building serving as a United States abortion center, featuring two windows and a central door. Fact Sheet: Gestational Breakdown of Brick-and-Mortar Abortion Centers in The United States October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates

You Might Also Be Interested In

Minimalist illustration of a small, flat-roofed building serving as a United States abortion center, featuring two windows and a central door.

Fact Sheet: Gestational Breakdown of Brick-and-Mortar Abortion Centers in The United States

charlotte-lozier-institute Charlotte Lozier Institute
November 9, 2026
A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image